Original Research Article

A comparative study of fractional carbon dioxide laser, narrowband ultraviolet B and topical tacrolimus 0.1% ointment versus narrowband ultraviolet B, topical tacrolimus 0.1% ointment in stable vitiligo

Anusha Putta¹*, Mohammed Waseem Javed²

¹Department of DVL, M. R. Medical College, Kalaburagi, Karnataka, India
²Department of DVL, KBNIMS, Kalaburagi, Karnataka, India

Received: 09 November 2019
Revised: 06 January 2020
Accepted: 07 January 2020

*Correspondence:
Dr. Anusha Putta,
E-mail: anushachowdary1993@gmail.com

ABSTRACT

Background: Vitiligo, an acquired pigmentary disorder of skin and mucous membrane characterized by well circumscribed depigmented macules that occur secondary to selective destruction of melanocytes. Fractional CO₂ laser system is a recent advancement in the treatment of vitiligo which works on the concept of fractional photothermolysis, in which microscopic treatment zones are created which help in increasing the penetration of topically applied agent which indirectly improves drug efficacy.

Methods: A comparative study was conducted on 40 patients of stable vitiligo attending OPD, Dept of DVL with fractional CO₂ laser, narrowband ultraviolet B (NBUVB) and topical tacrolimus 0.1% vs NBUVB, topical tacrolimus 0.1% for a duration of 4 months and patients were followed up for 12 weeks post treatment.

Results: Patients on Fractional CO₂ laser in combination with NBUVB and topical tacrolimus 0.1% ointment showed >50% improvement compared with other group, with duration for initiation of pigmentation being comparatively less.

Conclusions: The treatment protocol with CO₂ laser in combination with topical tacrolimus 0.1% cream and NBUVB for stable vitiligo was more effective than NBUVB and topical tacrolimus 0.1% alone and this study demonstrates that adding fractional CO₂ laser improves repigmentation rate of vitiliginous lesions.

Keywords: Fractional CO₂ laser, NBUVB, Tacrolimus, Vitiligo

INTRODUCTION

Vitiligo is an acquired, idiopathic disorder characterized by circumscribed depigmented macules and patches with or without leukotrichia. Its characterized by loss of functional melanocytes and melanin in epidermis.¹ The disease has an incidence of 0.5%-2% with no ethnic or sex predilection. Vitiligo has polygenic or autosomal dominant inheritance pattern with incomplete penetrance and variable expression.²-⁴ Based on clinical association of vitiligo with number of disorders, its considered to be autoimmune or autoinflammatory.⁵ People affected by vitiligo have a vast reduction of quality of life caused by color contrast between healthy pigmented skin and depigmented vitiliginous patches that give patients psychological problems.⁶,⁷ Medical treatment is the primary mode of therapy. Treatment can be broadly classified as medical, physical and surgical therapies and choice of treatment depends on extent, activity and refractoriness of disease. Combination of different modalities can be used to generate better outcomes compared to monotherapy.
Fractional CO₂ laser system is a recent advancement in the treatment of Vitiligo which works on the concept of Fractional photo thermolysis theory of laser skin resurfacing, in which microscopic treatment zones are created which help in increasing the penetration of topically applied agent which indirectly improves drug efficacy. The study was conducted to compare efficacy of fractional CO₂ laser, narrowband ultraviolet B (NBUVB), topical 0.1% tacrolimus ointment versus NBUVB and topical 0.1% tacrolimus ointment in patients with stable vitiligo.

**Figure 1: Generalised vitiligo.**

**Figure 2: Segmental vitiligo.**

**Figure 3: Mucosal vitiligo.**

**Figure 4: Acral vitiligo.**

**METHODS**

A comparative study was conducted on 40 patients of stable vitiligo attending OPD, department of Dermatology, Basaveshwara Teaching and General Hospital, Kalaburagi from March 2018 to September 2018. Study subjects were selected based on inclusion - exclusion criteria. Information was collected through proforma from each patient. Ethical clearance was taken for the study from ethical committee. Stable vitiligo. Patients with age >14 yrs and those with stable vitiligo were included and those with active skin infections, pregnant and nursing patients, patients currently on isotretinoin or have taken isotretinoin within the previous 12 months, active vitiligo patients with new, spreading lesions and positive koebner’s phenomenon were excluded. Statistical analysis was done by Chi square test using SPSS version 20.0 and p value <0.05 was taken as significant.

Initial clinical examination of the patient was done to determine the characteristics of vitiligo, including clinical type, number, size, and distribution. Patients were divided into 2 groups.

Group A patients were treated with CO₂ laser followed by NBUVB 0.5 J/cm² and tacrolimus ointment 0.1%. Group B patients were treated with NBUVB 0.5 J/cm² and tacrolimus ointment 0.1%.

**Preparation prior to procedure**

After obtaining written and informed consent, the skin was cleansed using mild cleanser. Local anesthetic cream was applied under occlusion for 1 hour to the entire area to be treated with laser. Eyes were covered with eye shields. Two passes of FCO₂ was used. Standard digital photographs will be taken at baseline, before each treatment session, and 16 weeks after the final treatment.

Lutronic fractional CO₂ was used with beam size 300 µ, peak power 30 W, beam mode static, pulse energy 100, density 150 spots per cm², total density 150 spots per cm².
Procedure in group A

FCO2 laser was delivered in above specifications, followed by NB-UVB 0.5 J/cm² and topical tacrolimus 0.1% ointment on same day of procedure and continued twice daily throughout the study period. CO₂ laser was repeated every 15 days and the phototherapy sessions were given twice weekly for a period of 4 months.

Procedure in group B

NB-UVB phototherapy twice weekly and tacrolimus 0.1% ointment twice a day for 4 months.

Evaluation of patient was scored using a quartile grading scale.

Table 1: Quartile grading scale.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Percentage of Repigmentation</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>Nil</td>
</tr>
<tr>
<td>1</td>
<td>1-25%</td>
<td>Minimal</td>
</tr>
<tr>
<td>2</td>
<td>26-50%</td>
<td>Moderate</td>
</tr>
<tr>
<td>3</td>
<td>51-75%</td>
<td>Good</td>
</tr>
<tr>
<td>4</td>
<td>&gt;75%</td>
<td>Excellent</td>
</tr>
</tbody>
</table>

RESULTS

Out of 40 patients of vitiligo, 26 were females and 14 were males. The commonest age group seen was 20-30 years. Age of onset of vitiligo in this study ranged from 20-30 years. The commonest site of lesion was over lower limbs. Family history was seen in 4 patients. In this study vitiligo was seen in association with hypothyroidism in 2 patients. Previous treatment history was seen in 31 patients.

Among 40 patients Grade 3 repigmentation was seen 48% in Group A and 23% in Group B. Time taken for initiation of repigmentation was <6 weeks in Group A in 38% and 10% in group B. Marginal type of repigmentation was the commonest type in Group A and perifollicular in Group B. Erythema and was common side effect in Group A and pruritis in Group B.
ointment and gave whole body NBUVB twice or thrice weekly for at least 2 months. The mean repigmentation was greater with tacrolimus. Wu et al, demonstrated that NBUVB irradiation stimulates the release of basic fibroblast growth factor and endothelin-1 from keratinocytes, which induces melanocyte proliferation.

In this study Grade 3 repigmentation was more in group A, 8 patients which was seen only in 2 patients of group B. Grade 1 repigmentation was more in group A, 7 patients compared to group A, 3 patients and no repigmentation was seen in 7 patients of group B, and in 2 patients of Group A. Duration of onset of repigmentation was <6 weeks in 8 patients of group A and 2 patients of group B, >6 weeks in 10 patients of group A and 11 patients of group B.

Njoo et al, in a study of 51 children with vitiligo reported more than 75% overall repigmentation in 27 patients (53%) after 1-year of treatment with NBUVB.

Marginal and diffuse type of repigmentation was common in group A and perifollicular in Group B. This was similar to the perifollicular pattern has been shown to be the most common pattern of repigmentation associated with NBUVB as is also seen with other UV based therapies like PUVA therapy and excimer laser. A study by Bhatnagar et al, compared the mean repigmentation for therapy resistant sites in patients exposed to NBUVB versus PUVA; it showed that after approximately 6 months of treatment (thrice weekly), 68% of repigmentation was possible using NBUVB versus 54% using PUVA.

**CONCLUSION**

Combining FCO2 laser, NBUVB and 0.1% tacrolimus ointment produces a significant improvement in stable vitiligo compared to NBUVB and 0.1% tacrolimus ointment.

**Funding:** No funding sources

**Conflict of interest:** None declared

**Ethical approval:** The study was approved by the institutional ethics committee

**REFERENCES**


